TrialBreast cancer research and treatment2021

Biomarkers of response to camrelizumab combined with apatinib: an analysis from a phase II trial in advanced triple-negative breast cancer patients.

Jieqiong Liu et al.PubMed ↗Publisher ↗

No numbers read from the abstract.